New Antiplatelet Agents: Platelet GPIIb/llla Antagonists

BS Coller, K Anderson… - Thrombosis and …, 1995 - thieme-connect.com
The success of aspirin, and more recently ticlopidine, in treating and preventing ischemic
complications of thrombosis has stimulated the search for more potent agents (1, 2). The …

The utility of animal models in the preclinical study of interventions to prevent human coronary artery restenosis: analysis and recommendations

GJ Johnson, TR Griggs… - Thrombosis and …, 1999 - thieme-connect.com
Small animal models have several advantageous characteristics, but those used in
preclinical restenosis research have lacked efficacy in predicting the success of …

Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach

E Nikolsky, R Mehran, G Dangas, M Fahy… - European heart …, 2007 - academic.oup.com
Aims Major bleeding after percutaneous coronary intervention (PCI) is an independent risk
factor for early and late mortality. We developed and validated a risk score predictive of …

Review of currently available GP IIb/IIIa inhibitors and their role in peripheral vascular interventions

PA Stangl, S Lewis - Seminars in interventional radiology, 2010 - thieme-connect.com
ABSTRACT The glycoprotein IIb/IIIa (GP IIb/IIIa) antagonists are the most recent additions to
the antiplatelet agents available to the interventional radiologist. The currently available GP …

[HTML][HTML] The stent decade: 1987 to 1997

SN Oesterle, R Whitbourn, PJ Fitzgerald, AC Yeung… - American heart …, 1998 - Elsevier
In January 1997, experts from the United States, Europe, and Japan gathered at Stanford
University to review their collective experience with intracoronary and noncoronary stenting …

Different response to balloon angioplasty of carotid and coronary arteries: effects on acute platelet deposition and intimal thickening

JJ Badimon, AF Ortiz, B Meyer, A Mailhac, JT Fallon… - Atherosclerosis, 1998 - Elsevier
PTCA is a well-established intervention to reduce the severity of atherosclerotic coronary
stenosis. Its primary success rate is seriously handicapped by the high incidence of late …

Anti-human vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs

S Kageyama, H Yamamoto, H Nakazawa… - Thrombosis research, 2001 - Elsevier
The antithrombotic and antihaemostatic effects of the monoclonal antibody against human
vWF (AJvW-2 Fab) were investigated in comparison with those of the monoclonal antibody …

Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban

SA Mousa, JM Bozarth, UP Naik… - British journal of …, 2001 - Wiley Online Library
A number of non‐peptide orally active RGD mimetic prodrug such as Orbofiban, Sibrafiban,
SR121566, Roxifiban and others entered into the clinical evaluation stage. Some of these …

Comparison of the effect of different platelet GPIIb/IIIa antagonists on the dynamics of platelet/fibrin-mediated clot strength induced using thromboelastography

SA Mousa, MS Forsythe - Thrombosis research, 2001 - Elsevier
The effect of various platelet glycoprotein IIb/IIIa (GPIIb/IIIa) antagonists on the dynamics of
platelet–fibrin clot formation and strength induced by various stimuli was measured by …

PAICA: a method for characterizing platelet-associated antibodies-its application to the study of idiopathic thrombocytopenic purpura and to the detection of platelet …

L Macchi, G Clofent-Sanchez, G Marit… - Thrombosis and …, 1996 - thieme-connect.com
In idiopathic thrombocytopenic purpura (ITP), autoantibodies reacting with antigens on the
platelet membrane bring about accelerated platelet destruction. We now report PAICA …